Detail akcie Inventiva online

Business Summary: Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Inventiva SA revenues increased from EUR41K to EUR4.5M. Net loss applicable to common stockholders increased from EUR49M to EUR175.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General & Administrative Expenses - Ot. increase of 99% to EUR12.4M (expense).